Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline Review, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline Review, H2 2015


  • Products Id :- GMDHC7280IDB
  • |
  • Pages: 203
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline Review, H2 2015', provides an overview of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Clostridium Difficile Infections (Clostridium Difficile Associated Disease)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview 9

Therapeutics Development 10

Pipeline Products for Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Overview 10

Pipeline Products for Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Comparative Analysis 11

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Therapeutics under Development by Companies 12

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Therapeutics under Investigation by Universities/Institutes 14

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Products under Development by Companies 18

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Products under Investigation by Universities/Institutes 22

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Companies Involved in Therapeutics Development 23

Absynth Biologics Limited 23

Actelion Ltd 24

Adenium Biotech ApS 25

AIMM Therapeutics B.V. 26

Akthelia pharmaceuticals ehf 27

AmpliPhi Biosciences Corporation 28

Angothera GmbH 29

Assembly Biosciences, Inc. 30

AvidBiotics Corp. 31

C3 Jian, Inc 32

Daiichi Sankyo Company, Limited 33

Evec, Inc. 34

GangaGen Inc. 35

ImmunoBiology Limited 36

Immuron Limited 37

Inovio Pharmaceuticals, Inc. 38

Intrexon Corporation 39

MedImmune, LLC 40

Merck & Co., Inc. 41

MGB Biopharma Limited 42

Microbiotix, Inc. 43

Micropharm Limited 44

Morphochem AG 45

Nanotherapeutics, Inc. 46

Novabiotics Limited 47

NovoBiotic Pharmaceuticals, LLC 48

Oragenics, Inc. 49

Pfizer Inc. 50

Procarta Biosystems Ltd 51

Prokarium Limited 52

Rebiotix Inc. 53

Sanofi Pasteur SA 54

Sarum Biosciences Limited 55

Sequella, Inc. 56

Seres Therapeutics, Inc. 57

Shire Plc 58

Sorrento Therapeutics, Inc. 59

Stellar Biotechnologies, Inc. 60

Summit Therapeutics Plc 61

Synthetic Biologics, Inc. 62

Valevia UK Limited 63

Valneva SE 64

VaxInnate Corporation 65

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Therapeutics Assessment 66

Assessment by Monotherapy Products 66

Assessment by Combination Products 67

Assessment by Target 68

Assessment by Mechanism of Action 70

Assessment by Route of Administration 72

Assessment by Molecule Type 74

Drug Profiles 76

(actoxumab + bezlotoxumab)-Drug Profile 76

ABCD-01-Drug Profile 77

actoxumab-Drug Profile 78

AKT-10081-Drug Profile 79

Antibodies for Enterocolitis-Drug Profile 80

AP-114-Drug Profile 81

AvR2-V10-Drug Profile 82

bezlotoxumab-Drug Profile 84

Biologic for Clostridium Difficile Enteropathy-Drug Profile 85

Biologic for Clostridium difficile Infections-Drug Profile 86

C-3CD17-Drug Profile 87

cadazolid-Drug Profile 88

Cdiff snare-Drug Profile 89

clostridium difficile vaccine-Drug Profile 90

Clostridium difficile vaccine-Drug Profile 91

clostridium difficile vaccine-Drug Profile 92

Clostridium difficile vaccine-Drug Profile 93

clostridium difficile vaccine-Drug Profile 94

Clostridium difficile vaccine-Drug Profile 95

Clostridium difficile vaccine-Drug Profile 96

Clostridium difficile vaccine-Drug Profile 97

clostridium difficile vaccine-Drug Profile 98

CRS-3123-Drug Profile 99

Drug for Clostridium difficile Infection-Drug Profile 100

Endolysin-Drug Profile 101

EV-029104-Drug Profile 103

EV-029105A-Drug Profile 104

fidaxomicin-Drug Profile 105

GBV-006-Drug Profile 108

IMM-529-Drug Profile 109

INS-001-Drug Profile 110

INX-201-Drug Profile 111

MB-101-Drug Profile 112

MBX-500-Drug Profile 113

MCB-3681-Drug Profile 115

MGBBP-3-Drug Profile 116

Monoclonal Antibodies for Clostridium difficile-Drug Profile 118

Monoclonal Antibody for Clostridium Difficile Infections-Drug Profile 119

Monoclonal Antibody to Inhibit Clostridium difficile Toxin A and Toxin B for Clostridium Difficile Infections-Drug Profile 120

MU-1140-Drug Profile 121

NP-432-Drug Profile 123

OraCAb-Drug Profile 124

P-2-A-Drug Profile 125

P-4A-Drug Profile 126

PF-06425090-Drug Profile 127

PolyCAb-Drug Profile 128

PRO-391-Drug Profile 129

ramoplanin-Drug Profile 130

RBX-2660-Drug Profile 131

ridinilazole-Drug Profile 133

SER-109-Drug Profile 135

SER-262-Drug Profile 136

Small Molecule to Inhibit Guanine Riboswitches for MRSA and Clostridium Difficile Infections-Drug Profile 137

Small Molecules for Clostridium Difficile Infections-Drug Profile 138

Small Molecules for Clostridium Difficile Infections-Drug Profile 139

Small Molecules to Inhibit CD Toxin A and Toxin B for Clostridium Difficile Infections-Drug Profile 140

Small Molecules to Inhibit DNA Synthesis for Infectious Diseases-Drug Profile 141

Small Molecules to Inhibit Dynamin for Clostridium Difficile Infections-Drug Profile 143

SMT-21829-Drug Profile 144

SQ-109-Drug Profile 145

SQ-641-Drug Profile 149

surotomycin-Drug Profile 150

SYN-004-Drug Profile 151

VAL-301-Drug Profile 152

VLA-84-Drug Profile 154

VP-20621-Drug Profile 156

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Recent Pipeline Updates 157

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Dormant Projects 186

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Discontinued Products 187

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Product Development Milestones 188

Featured News & Press Releases 188

Appendix 197

Methodology 197

Coverage 197

Secondary Research 197

Primary Research 197

Expert Panel Validation 197

Contact Us 197

Disclaimer 198

List of Tables

Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), H2 2015 15

Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Comparative Analysis, H2 2015 16

Number of Products under Development by Companies, H2 2015 17

Number of Products under Investigation by Universities/Institutes, H2 2015 19

Comparative Analysis by Late Stage Development, H2 2015 20

Comparative Analysis by Clinical Stage Development, H2 2015 21

Comparative Analysis by Early Stage Development, H2 2015 22

Products under Development by Companies, H2 2015 23

Products under Development by Companies, H2 2015 (Contd..1) 24

Products under Development by Companies, H2 2015 (Contd..2) 25

Products under Development by Companies, H2 2015 (Contd..3) 26

Products under Investigation by Universities/Institutes, H2 2015 27

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Absynth Biologics Limited, H2 2015 28

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Actelion Ltd, H2 2015 29

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Adenium Biotech ApS, H2 2015 30

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by AIMM Therapeutics B.V., H2 2015 31

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Akthelia pharmaceuticals ehf, H2 2015 32

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by AmpliPhi Biosciences Corporation, H2 2015 33

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Angothera GmbH, H2 2015 34

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Assembly Biosciences, Inc., H2 2015 35

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by AvidBiotics Corp., H2 2015 36

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by C3 Jian, Inc, H2 2015 37

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Daiichi Sankyo Company, Limited, H2 2015 38

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Evec, Inc., H2 2015 39

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by GangaGen Inc., H2 2015 40

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by ImmunoBiology Limited, H2 2015 41

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Immuron Limited, H2 2015 42

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Inovio Pharmaceuticals, Inc., H2 2015 43

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Intrexon Corporation, H2 2015 44

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by MedImmune, LLC, H2 2015 45

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Merck & Co., Inc., H2 2015 46

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by MGB Biopharma Limited, H2 2015 47

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Microbiotix, Inc., H2 2015 48

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Micropharm Limited, H2 2015 49

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Morphochem AG, H2 2015 50

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Nanotherapeutics, Inc., H2 2015 51

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Novabiotics Limited, H2 2015 52

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2015 53

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Oragenics, Inc., H2 2015 54

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Pfizer Inc., H2 2015 55

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Procarta Biosystems Ltd, H2 2015 56

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Prokarium Limited, H2 2015 57

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Rebiotix Inc., H2 2015 58

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Sanofi Pasteur SA, H2 2015 59

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Sarum Biosciences Limited, H2 2015 60

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Sequella, Inc., H2 2015 61

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Seres Therapeutics, Inc., H2 2015 62

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Shire Plc, H2 2015 63

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Sorrento Therapeutics, Inc., H2 2015 64

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Stellar Biotechnologies, Inc., H2 2015 65

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Summit Therapeutics Plc, H2 2015 66

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Synthetic Biologics, Inc., H2 2015 67

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Valevia UK Limited, H2 2015 68

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by Valneva SE, H2 2015 69

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Pipeline by VaxInnate Corporation, H2 2015 70

Assessment by Monotherapy Products, H2 2015 71

Assessment by Combination Products, H2 2015 72

Number of Products by Stage and Target, H2 2015 74

Number of Products by Stage and Mechanism of Action, H2 2015 76

Number of Products by Stage and Route of Administration, H2 2015 78

Number of Products by Stage and Molecule Type, H2 2015 80

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics-Recent Pipeline Updates, H2 2015 162

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Dormant Projects, H2 2015 191

Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Discontinued Products, H2 2015 192

List of Figures

Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), H2 2015 15

Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease)-Comparative Analysis, H2 2015 16

Number of Products under Development by Companies, H2 2015 17

Number of Products under Investigation by Universities/Institutes, H2 2015 19

Comparative Analysis by Clinical Stage Development, H2 2015 21

Comparative Analysis by Early Stage Products, H2 2015 22

Assessment by Monotherapy Products, H2 2015 71

Number of Products by Top 10 Targets, H2 2015 73

Number of Products by Stage and Top 10 Targets, H2 2015 73

Number of Products by Top 10 Mechanism of Actions, H2 2015 75

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 75

Number of Products by Routes of Administration, H2 2015 77

Number of Products by Stage and Routes of Administration, H2 2015 77

Number of Products by Top 10 Molecule Types, H2 2015 79

Number of Products by Stage and Top 10 Molecule Types, H2 2015 79

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Absynth Biologics Limited

Actelion Ltd

Adenium Biotech ApS

AIMM Therapeutics B.V.

Akthelia pharmaceuticals ehf

AmpliPhi Biosciences Corporation

Angothera GmbH

Assembly Biosciences, Inc.

AvidBiotics Corp.

C3 Jian, Inc

Daiichi Sankyo Company, Limited

Evec, Inc.

GangaGen Inc.

ImmunoBiology Limited

Immuron Limited

Inovio Pharmaceuticals, Inc.

Intrexon Corporation

MedImmune, LLC

Merck & Co., Inc.

MGB Biopharma Limited

Microbiotix, Inc.

Micropharm Limited

Morphochem AG

Nanotherapeutics, Inc.

Novabiotics Limited

NovoBiotic Pharmaceuticals, LLC

Oragenics, Inc.

Pfizer Inc.

Procarta Biosystems Ltd

Prokarium Limited

Rebiotix Inc.

Sanofi Pasteur SA

Sarum Biosciences Limited

Sequella, Inc.

Seres Therapeutics, Inc.

Shire Plc

Sorrento Therapeutics, Inc.

Stellar Biotechnologies, Inc.

Summit Therapeutics Plc

Synthetic Biologics, Inc.

Valevia UK Limited

Valneva SE

VaxInnate Corporation

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutic Products under Development, Key Players in Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics, Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Pipeline Overview, Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Pipeline, Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Pipeline Assessment

select a license

Single User License
USD 2000 INR 129140
Site License
USD 4000 INR 258280
Corporate User License
USD 6000 INR 387420

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com